SunTrust Banks Boosts Humana (NYSE:HUM) Price Target to $335.00

Humana (NYSE:HUM) had its target price increased by SunTrust Banks to $335.00 in a research note released on Thursday, The Fly reports. They currently have a hold rating on the insurance provider’s stock. SunTrust Banks also issued estimates for Humana’s Q4 2019 earnings at $2.22 EPS, FY2019 earnings at $17.78 EPS, Q1 2020 earnings at $4.80 EPS, Q2 2020 earnings at $5.94 EPS, Q3 2020 earnings at $5.04 EPS, Q4 2020 earnings at $2.86 EPS and FY2020 earnings at $18.64 EPS. The analysts noted that the move was a valuation call.

HUM has been the subject of several other research reports. Canaccord Genuity restated a buy rating on shares of Humana in a research note on Monday, October 21st. Berenberg Bank restated a buy rating on shares of Humana in a research note on Monday, October 21st. Cantor Fitzgerald upgraded Humana from a neutral rating to an overweight rating and lifted their price target for the company from $300.00 to $345.00 in a research note on Monday, August 12th. UBS Group lifted their price target on Humana from $266.00 to $317.00 and gave the company a neutral rating in a research note on Thursday, August 1st. Finally, Mizuho assumed coverage on Humana in a research note on Thursday, October 17th. They issued a buy rating and a $316.00 price target for the company. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and fourteen have issued a buy rating to the stock. Humana currently has an average rating of Buy and a consensus target price of $322.63.

Shares of Humana stock traded up $2.44 on Thursday, hitting $317.58. The company’s stock had a trading volume of 1,173,375 shares, compared to its average volume of 1,220,728. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.75 and a current ratio of 1.75. Humana has a 1 year low of $225.65 and a 1 year high of $342.03. The firm has a fifty day moving average price of $277.48 and a 200-day moving average price of $270.93. The company has a market capitalization of $39.82 billion, a price-to-earnings ratio of 21.83, a price-to-earnings-growth ratio of 1.27 and a beta of 0.85.

Humana (NYSE:HUM) last announced its quarterly earnings results on Wednesday, November 6th. The insurance provider reported $5.03 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $4.58 by $0.45. Humana had a return on equity of 22.47% and a net margin of 4.13%. The firm had revenue of $16.24 billion during the quarter, compared to analyst estimates of $16.15 billion. During the same quarter in the previous year, the business earned $4.58 EPS. Humana’s revenue for the quarter was up 14.3% compared to the same quarter last year. As a group, analysts forecast that Humana will post 17.75 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st will be paid a dividend of $0.55 per share. The ex-dividend date of this dividend is Monday, December 30th. This represents a $2.20 annualized dividend and a yield of 0.69%. Humana’s dividend payout ratio (DPR) is currently 15.12%.

In other Humana news, insider Brian P. Leclaire sold 7,239 shares of the business’s stock in a transaction that occurred on Thursday, August 22nd. The stock was sold at an average price of $289.70, for a total transaction of $2,097,138.30. Following the completion of the sale, the insider now directly owns 12,994 shares in the company, valued at approximately $3,764,361.80. The transaction was disclosed in a document filed with the SEC, which is available through this link. 0.54% of the stock is currently owned by insiders.

Institutional investors have recently modified their holdings of the company. Cornerstone Advisors Inc. lifted its holdings in Humana by 9.9% in the third quarter. Cornerstone Advisors Inc. now owns 388 shares of the insurance provider’s stock valued at $99,000 after acquiring an additional 35 shares during the last quarter. Lindbrook Capital LLC lifted its holdings in Humana by 12.0% in the third quarter. Lindbrook Capital LLC now owns 327 shares of the insurance provider’s stock valued at $84,000 after acquiring an additional 35 shares during the last quarter. Regentatlantic Capital LLC lifted its holdings in Humana by 0.4% in the second quarter. Regentatlantic Capital LLC now owns 9,617 shares of the insurance provider’s stock valued at $2,551,000 after acquiring an additional 42 shares during the last quarter. Ballentine Partners LLC lifted its stake in Humana by 2.5% during the third quarter. Ballentine Partners LLC now owns 1,751 shares of the insurance provider’s stock worth $448,000 after purchasing an additional 42 shares in the last quarter. Finally, Cim Investment Mangement Inc. lifted its stake in Humana by 4.3% during the second quarter. Cim Investment Mangement Inc. now owns 1,125 shares of the insurance provider’s stock worth $298,000 after purchasing an additional 46 shares in the last quarter. Institutional investors and hedge funds own 92.93% of the company’s stock.

Humana Company Profile

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

See Also: Trading on Margin

The Fly

Analyst Recommendations for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.